Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

s-coupled receptor signaling and sleep regulate integrin activation of human antigen-specific T cells.

Dimitrov S, Lange T, Gouttefangeas C, Jensen ATR, Szczepanski M, Lehnnolz J, Soekadar S, Rammensee HG, Born J, Besedovsky L.

J Exp Med. 2019 Mar 4;216(3):517-526. doi: 10.1084/jem.20181169. Epub 2019 Feb 12.

PMID:
30755455
2.

Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z.

PMID:
30733620
3.

Actively personalized vaccination trial for newly diagnosed glioblastoma.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W.

Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Erratum in: Nature. 2019 Feb;566(7745):E13.

PMID:
30568303
4.

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C.

Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018.

PMID:
30393582
5.

The fungal ligand chitin directly binds TLR2 and triggers inflammation dependent on oligomer size.

Fuchs K, Cardona Gloria Y, Wolz OO, Herster F, Sharma L, Dillen CA, Täumer C, Dickhöfer S, Bittner Z, Dang TM, Singh A, Haischer D, Schlöffel MA, Koymans KJ, Sanmuganantham T, Krach M, Roger T, Le Roy D, Schilling NA, Frauhammer F, Miller LS, Nürnberger T, LeibundGut-Landmann S, Gust AA, Macek B, Frank M, Gouttefangeas C, Dela Cruz CS, Hartl D, Weber AN.

EMBO Rep. 2018 Dec;19(12). pii: e46065. doi: 10.15252/embr.201846065. Epub 2018 Oct 18.

PMID:
30337494
6.

Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation.

Dimitrov S, Gouttefangeas C, Besedovsky L, Jensen ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG.

Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5536-E5545. doi: 10.1073/pnas.1720714115. Epub 2018 May 29.

7.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Bidmon N, Kind S, Welters MJP, Joseph-Pietras D, Laske K, Maurer D, Hadrup SR, Schreibelt G, Rae R, Sahin U, Gouttefangeas C, Britten CM, van der Burg SH.

J Immunol Methods. 2018 Jul;458:74-82. doi: 10.1016/j.jim.2018.04.007. Epub 2018 Apr 21.

8.

Personalized cancer vaccines: adjuvants are important, too.

Gouttefangeas C, Rammensee HG.

Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918. doi: 10.1007/s00262-018-2158-4. Epub 2018 Apr 11. Review.

PMID:
29644387
9.

Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.

Rausch S, Gouttefangeas C, Hennenlotter J, Laske K, Walter K, Feyerabend S, Chandran PA, Kruck S, Singh-Jasuja H, Frick A, Kröger N, Stevanović S, Stenzl A, Rammensee HG, Bedke J.

Eur Urol Focus. 2017 Oct 4. pii: S2405-4569(17)30213-4. doi: 10.1016/j.euf.2017.09.009. [Epub ahead of print]

PMID:
28988765
10.

Caramel flavour perception: Impact of the non-volatile compounds on sensory properties and in-vitro aroma release.

Paravisini L, Moretton C, Gouttefangeas C, Nigay H, Dacremont C, Guichard E.

Food Res Int. 2017 Oct;100(Pt 1):209-215. doi: 10.1016/j.foodres.2017.07.003. Epub 2017 Jul 4. No abstract available.

PMID:
28873680
11.

Automated Analysis of Flow Cytometry Data to Reduce Inter-Lab Variation in the Detection of Major Histocompatibility Complex Multimer-Binding T Cells.

Pedersen NW, Chandran PA, Qian Y, Rebhahn J, Petersen NV, Hoff MD, White S, Lee AJ, Stanton R, Halgreen C, Jakobsen K, Mosmann T, Gouttefangeas C, Chan C, Scheuermann RH, Hadrup SR.

Front Immunol. 2017 Jul 26;8:858. doi: 10.3389/fimmu.2017.00858. eCollection 2017.

12.

A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex-Peptide Monomers by Flow Cytometry.

Chandran PA, Heidu S, Zelba H, Schmid-Horch B, Rammensee HG, Pascolo S, Gouttefangeas C.

Front Immunol. 2017 Feb 8;8:96. doi: 10.3389/fimmu.2017.00096. eCollection 2017.

13.

Erratum to "Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient".

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2017 Jan;66(1):252-253. doi: 10.1016/j.jhep.2016.10.021. Epub 2016 Nov 15. No abstract available.

PMID:
27863814
14.

Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient.

Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG.

J Hepatol. 2016 Oct;65(4):849-855. doi: 10.1016/j.jhep.2016.06.027. Epub 2016 Jul 7. Erratum in: J Hepatol. 2017 Jan;66(1):252-253.

15.

Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay.

Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas C.

Cytometry B Clin Cytom. 2018 Mar;94(2):342-353. doi: 10.1002/cyto.b.21397. Epub 2016 Jul 22.

16.

Soluble heat shock protein 70 members in patients undergoing allogeneic hematopoietic cell transplantation.

Mirza N, Prokop L, Kowalewski D, Gouttefangeas C, Faul C, Bethge WA, Vogel W, Kanz L, Rammensee HG, Haen SP.

Transpl Immunol. 2016 May;36:25-31. doi: 10.1016/j.trim.2016.03.003. Epub 2016 Mar 25.

PMID:
27020764
17.

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.

Mandruzzato S, Brandau S, Britten CM, Bronte V, Damuzzo V, Gouttefangeas C, Maurer D, Ottensmeier C, van der Burg SH, Welters MJ, Walter S.

Cancer Immunol Immunother. 2016 Feb;65(2):161-9. doi: 10.1007/s00262-015-1782-5. Epub 2016 Jan 4.

18.

Profiling of primary peripheral blood- and monocyte-derived dendritic cells using monoclonal antibodies from the HLDA10 Workshop in Wollongong, Australia.

Autenrieth SE, Grimm S, Rittig SM, Grünebach F, Gouttefangeas C, Bühring HJ.

Clin Transl Immunology. 2015 Nov 13;4(11):e50. doi: 10.1038/cti.2015.29. eCollection 2015 Nov.

19.

A framework for T cell assays.

Britten CM, van der Burg SH, Gouttefangeas C.

Oncotarget. 2015 Nov 3;6(34):35143-4. doi: 10.18632/oncotarget.6181. No abstract available.

20.

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28.

21.

A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.

Anastasopoulou EA, Voutsas IF, Keramitsoglou T, Gouttefangeas C, Kalbacher H, Thanos A, Papamichail M, Perez SA, Baxevanis CN.

Cancer Immunol Immunother. 2015 Sep;64(9):1123-36. doi: 10.1007/s00262-015-1717-1. Epub 2015 May 31.

PMID:
26026288
22.

Generation of TCR-engineered T cells and their use to control the performance of T cell assays.

Bidmon N, Attig S, Rae R, Schröder H, Omokoko TA, Simon P, Kuhn AN, Kreiter S, Sahin U, Gouttefangeas C, van der Burg SH, Britten CM.

J Immunol. 2015 Jun 15;194(12):6177-89. doi: 10.4049/jimmunol.1400958. Epub 2015 May 8.

23.

Thinking outside the gate: single-cell assessments in multiple dimensions.

Kvistborg P, Gouttefangeas C, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJ, Ferrari G, Brinkman RR, Britten CM.

Immunity. 2015 Apr 21;42(4):591-2. doi: 10.1016/j.immuni.2015.04.006. No abstract available.

24.

Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters.

Gouttefangeas C, Chan C, Attig S, Køllgaard TT, Rammensee HG, Stevanović S, Wernet D, thor Straten P, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2015 May;64(5):585-98. doi: 10.1007/s00262-014-1649-1. Epub 2015 Feb 18.

25.

Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells.

Hadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C.

Cytometry A. 2015 Jan;87(1):37-48. doi: 10.1002/cyto.a.22575. Epub 2014 Oct 8.

26.

Characterisation of the volatile fraction of aromatic caramel using heart-cutting multidimensional gas chromatography.

Paravisini L, Prot A, Gouttefangeas C, Moretton C, Nigay H, Dacremont C, Guichard E.

Food Chem. 2015 Jan 15;167:281-9. doi: 10.1016/j.foodchem.2014.06.101. Epub 2014 Jul 3.

PMID:
25148990
27.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH.

Cancer Immunol Immunother. 2014 Nov;63(11):1199-211. doi: 10.1007/s00262-014-1593-0. Epub 2014 Aug 19.

28.

Alternative variants of human HYDIN are novel cancer-associated antigens recognized by adaptive immunity.

Laske K, Shebzukhov YV, Grosse-Hovest L, Kuprash DV, Khlgatian SV, Koroleva EP, Sazykin AY, Penkov DN, Belousov PV, Stevanovic S, Vass V, Walter S, Eisel D, Schmid-Horch BD, Nedospasov SA, Rammensee HG, Gouttefangeas C.

Cancer Immunol Res. 2013 Sep;1(3):190-200. doi: 10.1158/2326-6066.CIR-13-0079. Epub 2013 Jul 5.

29.

Managing Multi-center Flow Cytometry Data for Immune Monitoring.

White S, Laske K, Welters MJ, Bidmon N, van der Burg SH, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan C.

Cancer Inform. 2015 Jun 10;13(Suppl 7):111-22. doi: 10.4137/CIN.S16346. eCollection 2014.

30.

Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes.

Sittig SP, Køllgaard T, Grønbæk K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P.

Oncoimmunology. 2013 Sep 1;2(9):e26014. Epub 2013 Sep 26.

31.

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.

Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C, Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, Svane IM.

Clin Cancer Res. 2014 Jan 1;20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. Epub 2013 Nov 11.

32.

AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.

Perez SA, Anastasopoulou EA, Tzonis P, Gouttefangeas C, Kalbacher H, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2013 Oct;62(10):1599-608. doi: 10.1007/s00262-013-1461-3. Epub 2013 Aug 10.

PMID:
23934022
33.

Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples.

Cron A, Gouttefangeas C, Frelinger J, Lin L, Singh SK, Britten CM, Welters MJ, van der Burg SH, West M, Chan C.

PLoS Comput Biol. 2013;9(7):e1003130. doi: 10.1371/journal.pcbi.1003130. Epub 2013 Jul 11.

34.

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy.

Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanović S, Behnes CL, Stenzl A.

World J Urol. 2014 Feb;32(1):31-8. doi: 10.1007/s00345-013-1033-3. Epub 2013 Feb 12. Review.

35.

A vaccine in renal cell carcinoma: are we nearing reality?

Bedke J, Gouttefangeas C, Kruck S, Stenzl A.

Expert Rev Anticancer Ther. 2012 Dec;12(12):1503-5. doi: 10.1586/era.12.139. No abstract available.

PMID:
23253216
36.

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM.

Cancer Immunol Immunother. 2013 Apr;62(4):615-27. doi: 10.1007/s00262-012-1359-5. Epub 2012 Nov 9.

37.

The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.

Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2013 Mar;62(3):489-501. doi: 10.1007/s00262-012-1351-0. Epub 2012 Sep 18.

38.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

39.

Harmonization of the intracellular cytokine staining assay.

Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH.

Cancer Immunol Immunother. 2012 Jul;61(7):967-78. doi: 10.1007/s00262-012-1282-9. Epub 2012 May 22.

40.

More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C.

Clin Dev Immunol. 2011;2011:160250. doi: 10.1155/2011/160250. Epub 2011 Dec 29. Review.

41.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

42.

Harmonization of immune biomarker assays for clinical studies.

van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.

Sci Transl Med. 2011 Nov 9;3(108):108ps44. doi: 10.1126/scitranslmed.3002785. Review.

PMID:
22072636
43.

[Prostate carcinoma: vaccination as a new option for treatment].

Bedke J, Gouttefangeas C, Stenzl A.

Urologe A. 2012 Jan;51(1):44-9. doi: 10.1007/s00120-011-2712-6. Review. German.

PMID:
21989588
44.

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.

Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG.

Int J Cancer. 2012 Jul 1;131(1):140-9. doi: 10.1002/ijc.26365. Epub 2011 Sep 14.

45.

Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation.

Haen SP, Gouttefangeas C, Schmidt D, Boss A, Clasen S, von Herbay A, Kosan B, Aebert H, Pereira PL, Rammensee HG.

Cell Stress Chaperones. 2011 Sep;16(5):495-504. doi: 10.1007/s12192-011-0261-y. Epub 2011 Mar 26.

46.

CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.

Singh SK, Laske K, Gouttefangeas C, Britten CM, Welters MJ.

Cancer Immunol Immunother. 2011 Mar;60(3):443-50. doi: 10.1007/s00262-010-0947-5. Epub 2010 Nov 23. No abstract available.

PMID:
21104411
47.

Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation.

Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanović S, Pereira PL, Rammensee HG, Gouttefangeas C.

Int J Cancer. 2011 Jun 1;128(11):2653-62. doi: 10.1002/ijc.25601. Epub 2010 Oct 8.

48.

Modeling flow cytometry data for cancer vaccine immune monitoring.

Frelinger J, Ottinger J, Gouttefangeas C, Chan C.

Cancer Immunol Immunother. 2010 Sep;59(9):1435-41. doi: 10.1007/s00262-010-0883-4. Epub 2010 Jun 19. Review.

49.

Response definition criteria for ELISPOT assays revisited.

Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15.

50.

Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program.

Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM.

Cancer Immunol Immunother. 2010 Apr;59(4):619-27. doi: 10.1007/s00262-009-0814-4. Epub 2010 Jan 6.

Supplemental Content

Loading ...
Support Center